Study of antirestenosis with the biodivYsio dexamethasone-eluting stent (STRIDE): A first-in-human multicenter pilot trial

Xiaoshun Liu, Yanming Huang, Claude Hanet, Michel Vandormael, Victor Legrand, Joseph Dens, Jean Luc Vandenbossche, Luc Missault, Christiaan Vrints, Ivan De Scheerder

Résultats de recherche: Contribution à un journal/une revueArticleRevue par des pairs

Résumé

The aim of this multicenter pilot study was to evaluate the acute safety and efficacy of the dexamethasone-eluting stent (0.5 μg/mm2 of stent) implanted in patients with de novo single-vessel disease. This study included 71 patients, 42% of whom had unstable angina pectoris. An appropriately sized BiodivYsio Matrix Lo stent loaded with a total dexamethasone dose of 0.5 μg/mm2 of stent was used. Technical device success rate was 95%. Six-month MACE occurred in two patients (3.3%). Binary restenosis rate was 13.3%. Late loss was 0.45. Late loss and percent diameter stenosis were lower in the unstable angina pectoris patients compared to the stable patients (0.32 ± 0.39 vs. 0.60 ± 0.55 mm, P < 0.07, and 26.86 ± 14 vs. 38.40 ± 16%, P < 0.02). This study demonstrated the feasibility and safety of the implantation of a dexamethasone-eluting stent and its effect on in-stent neointimal hyperplasia.

langue originaleAnglais
Pages (de - à)172-178
Nombre de pages7
journalCatheterization and Cardiovascular Interventions
Volume60
Numéro de publication2
Les DOIs
Etat de la publicationPublié - 1 oct. 2003
Modification externeOui

Empreinte digitale Examiner les sujets de recherche de « Study of antirestenosis with the biodivYsio dexamethasone-eluting stent (STRIDE): A first-in-human multicenter pilot trial ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation